Deborah Moorad is the CEO of CorriXR Therapeutics, an oncology-focused biotherapeutics development company focused on overcoming drug resistance. Moorad is also the Entrepreneur-in-Residence (EIR) at Cortado Ventures, an early-stage venture capital firm investing in ambitious, growth driven companies.
Moorad has a proven track record creating and implementing strategies that bridge the gap between science and the boardroom, leading global cross-functional teams, managing board of directors, and developing trusted relationships that result in company acquisition. Most notable was her tenure as CEO of Nature Technology Corp., whose technology (HyperGRO, Nanoplasmid, and REVIVER) is used by leading pharmaceutical/biotechnology, including Genentech and Poseida Therapeutics, as well as nearly every contract development and manufacturing organization (CDMO) in the gene therapy/genomic medicine space. Under Moorad’s tenure, Nature Technology Corp. was acquired in a record multiplier transaction by Aldevron, a Danaher Company. Other career highlights include managing and leading the post-merger and management of the global KOL’s for Dentsply Sirona. The Dentsply International and Sirona Dental Systems merger notched $5.6 billion. Moorad also led a repurposed drug (OKN-007) from animal studies to clinical trial for glioblastoma multiforme, which was later acquired, and patients are still being treated using this therapy.
Moorad has a passion for science as well as her community. She has long been committed to cultivating the next generation of leaders. She mentors numerous companies on product development and business strategy; mentoring women interested in entrepreneurship and science; as well as a company-appointed mentor for the Master of Business Administration students at the University of Oklahoma.
